Salix and Colon Cancer Coalition Join Forces for 'Faces of Blue' Story Series to Raise Awareness of Colorectal Cancer Screenings

 
 

The Colon Cancer Coalition, a national nonprofit organization focusing on grass roots efforts to increase screening and awareness for colorectal cancer, and Salix Pharmaceuticals ("Salix"), the gastroenterology (GI) business of Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, are joining for the second consecutive year to raise awareness of the importance of colorectal cancer screenings. The Faces of Blue campaign will highlight the personal stories of patients and survivors touched by colorectal cancer to encourage preventive colorectal cancer screening.

 
 

   

 
 

In May 2021 , the United States Preventive Services Task Force lowered the colorectal cancer screening age to 45 from 50 for those of average risk, matching the American Cancer Society's guideline recommendation that was released in 2018. Approximately 45 million Americans are now eligible for a potentially life-saving colorectal cancer screening, and this new guidance emphasizes the need for awareness programs to educate patients about risk factors and the importance of on-time screening for early detection.

 

"Personal stories resonate and can help influence behavior," notes Chris Evans , president, Colon Cancer Coalition. "Over the last decade the Colon Cancer Coalition has shared stories to encourage screening for colorectal cancer. Now that the recommended screening age has been lowered to age 45, there is a new group of people who need to hear this life-saving message."

 

"Salix and the Colon Cancer Coalition are teaming up to help reduce the impact of colorectal cancer on the at-risk population by encouraging preventative screening that can lead to early detection," said Robert Spurr , president, Salix. "We're honored to support the Faces of Blue story series, and we are launching new resources and social media partnerships to encourage and empower patients to take preventive action for their health by scheduling a colonoscopy."

 

Salix is also launching a new educational website during the month of March and partnering with social influencers to educate people about the risks of colorectal cancer and stress the importance of early, life-saving screenings.

 

The 2022 #FacesOfBlue story series will be published regularly throughout Colorectal Cancer Awareness Month and semi-monthly throughout the rest of the year. These stories are posted to the Colon Cancer Coalition's website and will then be shared by both the Coalition and Salix on social media accounts.

 

To learn more about colorectal cancer and the importance of screening, visit ColonCancerCoalition.org .

 

  About the Colon Cancer Coalition
The Colon Cancer Coalition is a non-profit organization based in Minneapolis, Minn. , dedicated to encouraging screening and raising awareness for colon cancer. The organization's signature Get Your Rear in Gear® and Tour de Tush® events are volunteer-driven in communities throughout the United States . Since 2004, millions of dollars have been granted by the Colon Cancer Coalition to local programs that promote early prevention, screening and patient support services for this disease. By making the words colon, colorectal and colonoscopy a part of the everyday language, we believe we can overcome the fear and decrease deaths from this largely preventable cancer. For more information, visit ColonCancerCoalition.org .   

 

  About Faces of Blue   
The Faces of Blue Series, in its 11th year, features the personal stories of patients, survivors and others touched by colorectal cancer. The Colon Cancer Coalition features a special place on its website dedicated to this shared colorectal cancer experience. By publishing these accounts of courage, endurance, strength and even humor, the Colon Cancer Coalition hopes to share a common experience and provide encouragement for all affected by this disease. To read these stories of colorectal cancer resilience and perseverance, visit ColonCancerCoalition.org/FacesOfBlue .

 

  About Salix
Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey . For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn .

 

  About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .

 

  ©2022 Salix Pharmaceuticals or its affiliates.
  SAL.0029.USA.22  

 
 
        
 

   Colon Cancer Coalition Media Contact:   

 
 

   Bausch Health Media Contact:   

 
 

  Erin Peterson  

 
 

  Lainie Keller  

 
 

   erin@coloncancercoalition.org   

 
 

   Lainie.keller@bauschhealth.com   

 
 

  (651) 247-4023  

 
 

  (908) 927-1198  

 
 
 
 

  Colon Cancer Coalition 

 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/salix-and-colon-cancer-coalition-join-forces-for-faces-of-blue-story-series-to-raise-awareness-of-colorectal-cancer-screenings-301492217.html  

 

SOURCE Bausch Health Companies Inc.

 
 

News Provided by PR Newswire via QuoteMedia

BHC:CA,BHC
The Conversation (0)
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

 

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC). The data will be presented at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on Sunday, May 19, 2024, in Washington, D.C

 

"We are pleased to present late-breaking data on Amiselimod, our investigational, oral, sphingosine 1-phosphate (S1P) receptor modulator as a potential treatment for the induction of remission in UC," said Tage Ramakrishna, M.D., Chief Medical Officer and President of Research & Development, Bausch Health. "The abstract underscores our steadfast commitment to developing new and innovative therapies for patients with UC."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters

Bausch Health Announces Updates Related to Norwich XIFAXAN Matters

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigation with Norwich Pharmaceuticals, Inc

With respect to the April 11, 2024, decision of the US Court of Appeals for the Federal Circuit, both Bausch Health and Norwich have filed petitions for panel rehearing or rehearing en banc. The Company anticipates a decision on whether a rehearing will be granted within the next three months.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×